胃癌分子靶向药物及免疫检查点抑制剂临床研究和应用进展  

Clinical research and advances in application of molecular targeted therapies and immune checkpoint inhibitors in gastric cancer

作　　者：陈丽丽 杨扬[1] 夏曦[1] 吴秀伟[1] CHEN Li-li;YANG Yang;XIA Xi;WU Xiu-wei(Department of Medical Oncology,the Second Affiliated Hospital of Anhui Medical University,Hefei 230000,China)

机构地区：[1]安徽医科大学第二附属医院肿瘤中心,合肥230000

出　　处：《西南医科大学学报》2021年第5期538-544,共7页Journal of Southwest Medical University

基　　金：安徽省博士后基金项目(2020A392)。

摘　　要：近年来关于胃癌发病分子机制的研究越来越多,针对不同信号传导途径的新靶点药物相继开展了国际多中心临床研究,部分药物已在临床广泛应用,改变了胃癌的传统治疗模式。继曲妥珠单抗联合化疗治疗HER-2阳性进展期胃癌取得阳性结果,后线靶向HER-2的抗体偶联药物及新型单克隆抗体不断问世。除此之外,靶向血管生成、HGF/c-Met、PI3K、PARP、FGFR2b、CLDN18.2等药物以及免疫检查点抑制剂的临床研究正在进行中。本文对近年胃癌分子靶向治疗和免疫检查点抑制剂的研究现状及临床应用进行综述。In recent years,there have been more and more studies on the molecular mechanism of gastric can⁃cer.Many international centers have carried out clinical research on new targeted drugs aiming at different signal transduction pathways,and some drugs have been widely used in clinical practice,changing the traditional therapeu⁃tic paradigm for gastric cancer.Following the positive results of trastuzumab combined chemotherapy in the treat⁃ment of HER2-positive advanced gastric cancer,antibody-drug conjugates and novel monoclonal antibodies target⁃ing HER2 have been developed continuously.In addition,several agents targeting angiogenesis,HGF/c-Met,PI3K,PARP,FGFR2b,CLDN18.2,and immune checkpoint inhibitors are currently subjected to clinical trials.This article reviews the current studies and clinical application of molecular targeted therapies and immune checkpoint inhibi⁃tors in gastric cancer.

关 键 词：胃癌 胃食管结合部腺癌 分子靶向治疗 免疫检查点抑制剂 

分 类 号：R735.2[医药卫生—肿瘤]